XML 72 R60.htm IDEA: XBRL DOCUMENT
v3.23.1

Commitments and Contingencies - Contingencies - Additional Information (Detail) € in Millions |  |  |  |  |  | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | 48 Months Ended |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Dec. 31, 2022 USD ($) | Nov. 30, 2022 USD ($) | Nov. 09, 2022 USD ($) | Aug. 05, 2021 USD ($) | Jul. 21, 2021 USD ($) | Sep. 30, 2013 USD ($) | Apr. 30, 2013 USD ($) | Aug. 31, 2012 USD ($) | Dec. 31, 2010 USD ($) | Mar. 31, 2023 USD ($) | Sep. 30, 2021 USD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2020 USD ($) | Dec. 31, 2019 USD ($) | Dec. 31, 2017 USD ($) | Aug. 21, 2022 USD ($) | Dec. 31, 2022 EUR (€) | Jul. 08, 2021 USD ($) | Aug. 31, 2019 USD ($) | Jul. 31, 2008 USD ($) | Feb. 28, 2005 USD ($)
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Damages assessment |  |  |  |  |  |  |  |  |  | $ 235,500,000 |  |  |  |  |  |  |  |  |  |  |  |
Annual sales at the time of settlement |  |  |  |  |  |  |  |  |  | 700,000,000 |  |  |  |  |  |  |  |  |  | $ 350,000,000 |  |
Annual sales of Effexor |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 2,600,000,000 |  |  |  |  |
Annual sales of Lamictal |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 2,300,000 | $ 950,000,000
Annual sales of Niaspan |  |  |  |  |  | $ 1,100,000,000 | $ 416,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual sales of Actos |  |  |  |  |  |  |  | $ 2,800,000,000 | $ 3,700,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Annual sales of Acto plus |  |  |  |  |  |  |  | $ 430,000,000 | $ 500,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Litigation settlement amount |  | $ 4,250,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual Sales Of Sensipar |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,400,000,000 |  |  |  |  |  |  |
Litigation settlement amount awarded distribution period |  | 13 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual sales of Copaxone |  |  |  |  |  |  |  |  |  |  |  |  | $ 373,000,000 |  |  |  |  |  |  |  |  |
Generic modafinil, and imposed fines amount | $ 4,186,000,000 |  |  |  |  |  |  |  |  | 4,299,000,000 |  | $ 4,186,000,000 |  |  |  |  |  | € 60.5 |  |  |  |
Loss Contingency Accrual, Provision |  |  |  | $ 235,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual sales of the time of settlement of viread |  |  |  |  |  |  |  |  |  | 582,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Annual sales of the time of settlement of Truvada |  |  |  |  |  |  |  |  |  | 2,400,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Annual sales of the time of settlement of Atripla |  |  |  |  |  |  |  |  |  | 2,900,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Annual sales of the time of New launch of viread |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 728,000,000 |  |  |  |  |  |
Annual sales of the time of New launch of Truvada |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 2,100,000,000 |  |  |  |  |  |  |  |
Annual sales of the time of New launch of Atripla |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 444,000,000 |  |  |  |  |  |  |  |
Annual sales of Colcrys |  |  |  |  |  |  |  |  |  |  |  | $ 187,000,000 |  |  |  |  |  |  |  |  |  |
Litigation Settlement Amount Distributable In Kind |  | $ 1,200,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Accrual for Environmental Loss Contingencies |  |  |  |  |  |  |  |  |  | $ 300,000 |  |  |  |  |  |  |  |  |  |  |  |
Environmental Loss Contingency, Statement of Financial Position [Extensible Enumeration] |  |  |  |  |  |  |  |  |  | Liabilities, Current |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies On Environmental Laws Penalty |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,400,000 |  |  |
Percentage of the population of the participating states |  |  |  |  |  |  |  |  |  | 98.00% |  |  |  |  |  |  |  |  |  |  |  |
Percentage of the litigating subdivisions have chosen to participate in Teva's nationwide settlement |  |  |  |  |  |  |  |  |  | 99.00% |  |  |  |  |  |  |  |  |  |  |  |
Annual Sales Of Revlimid |  |  |  |  |  |  |  |  |  | $ 3,500,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Annual Sales At The Time Of Nuvigil Entered Into First Settlement Of With AN ANDA Filer | 300,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual Sales Of EpiPen | 600,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingency Claims Dismissed Value Paid To Each State Proportional To Its Share Of National Population | $ 1,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage Of Share Of The National Population | 1.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentgae of amount in cash settlement |  | 20.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Litigation Settlement Amount Distributable in cash |  | $ 240,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingency, Damages Awarded, Value |  |  | $ 176,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Four Other Defendants Other Than Teva [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency payment |  |  |  |  | $ 26,000,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Nationwide Settlement [Member] | Four Other Defendants Other Than Teva [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Litigation settlement amount awarded distribution period |  |  |  |  | 18 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Europe [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Damage claimed |  |  |  |  |  |  |  |  |  |  | $ 50,000,000 |  |  |  |  |  |  |  |  |  |  |
Eosinophilic Esophagitis [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Damage claimed |  |  |  |  |  |  |  |  |  |  | 200,000,000 |  |  |  |  |  |  |  |  |  |  |
Eosinophilic Esophagitis [Member] | United States [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Damage claimed |  |  |  |  |  |  |  |  |  |  | $ 150,000,000 |  |  |  |  |  |  |  |  |  |  |
AndroGel Rate at 1% [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual sales at the time of settlement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 140,000,000 |  |

X
- Definition Annual sales at The time of nuvigil entered into first settlement of with AN ANDA hiler. + References No definition available. + Details
Name: | teva_AnnualSalesAtTheTimeOfNuvigilEnteredIntoFirstSettlementOfWithAnAndaFiler
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Annual sales at time of settlement. + References No definition available. + Details
Name: | teva_AnnualSalesAtTimeOfSettlement
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Annual sales of Acto plus. + References No definition available. + Details
Name: | teva_AnnualSalesOfActoplus
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Annual sales of Actos. + References No definition available. + Details
Name: | teva_AnnualSalesOfActos
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Annual sales of colcrys. + References No definition available. + Details
Name: | teva_AnnualSalesOfColcrys
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Annual Sales Of Copaxone. + References No definition available. + Details
Name: | teva_AnnualSalesOfCopaxone
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Annual sales of effexor. + References No definition available. + Details
Name: | teva_AnnualSalesOfEffexor
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Annual sales of EpiPen. + References No definition available. + Details
Name: | teva_AnnualSalesOfEpipen
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Annual sales of Lamictal. + References No definition available. + Details
Name: | teva_AnnualSalesOfLamictal
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Annual sales of Niaspan. + References No definition available. + Details
Name: | teva_AnnualSalesOfNiaspan
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Annual sales of revlimid. + References No definition available. + Details
Name: | teva_AnnualSalesOfRevlimid
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents Annual Sales Of Sensipar. + References No definition available. + Details
Name: | teva_AnnualSalesOfSensipar
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Annual sales of the time of new launch of Atripla. + References No definition available. + Details
Name: | teva_AnnualSalesOfTheTimeOfNewLaunchOfAtripla
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Annual sales of the time of New launch of truvada. + References No definition available. + Details
Name: | teva_AnnualSalesOfTheTimeOfNewLaunchOfTruvada
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Annual sales of the time of new launch of viread. + References No definition available. + Details
Name: | teva_AnnualSalesOfTheTimeOfNewLaunchOfViread
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Annual sales of the time of settlement of atripla. + References No definition available. + Details
Name: | teva_AnnualSalesOfTheTimeOfSettlementOfAtripla
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Annual sales of the time of settlement of truvada. + References No definition available. + Details
Name: | teva_AnnualSalesOfTheTimeOfSettlementOfTruvada
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Annual sales of the time of settlement of viread. + References No definition available. + Details
Name: | teva_AnnualSalesOfTheTimeOfSettlementOfViread
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Commitment And Contingencies [Line Items] + References No definition available. + Details
Name: | teva_CommitmentAndContingenciesLineItems
Namespace Prefix: | teva_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Damages assessment. + References No definition available. + Details
Name: | teva_DamagesAssessment
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Litigation settlement amount awarded distribution period. + References No definition available. + Details
Name: | teva_LitigationSettlementAmountAwardedDistributionPeriod
Namespace Prefix: | teva_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Litigation settlement amount distributable in cash. + References No definition available. + Details
Name: | teva_LitigationSettlementAmountDistributableInCash
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Litigation settlement amount distributableIn kind. + References No definition available. + Details
Name: | teva_LitigationSettlementAmountDistributableinKind
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Litigation settlement amount payable in cash percentage + References No definition available. + Details
Name: | teva_LitigationSettlementAmountPayableInCashPercentage
Namespace Prefix: | teva_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Loss contingencies on environmental laws penalty. + References No definition available. + Details
Name: | teva_LossContingenciesOnEnvironmentalLawsPenalty
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Loss contingency claims dismissed value paid to each state proportional to its share of national population + References No definition available. + Details
Name: | teva_LossContingencyClaimsDismissedValuePaidToEachStateProportionalToItsShareOfNationalPopulation
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of share of the national population. + References No definition available. + Details
Name: | teva_PercentageOfShareOfTheNationalPopulation
Namespace Prefix: | teva_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of the litigating subdivisions have chosen to participate in teva's nationwide settlement. + References No definition available. + Details
Name: | teva_PercentageOfTheLitigatingSubdivisionsHaveChosenToParticipateInTevasNationwideSettlement
Namespace Prefix: | teva_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of the population of the participating states. + References No definition available. + Details
Name: | teva_PercentageOfThePopulationOfTheParticipatingStates
Namespace Prefix: | teva_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Total costs accrued as of the balance sheet date for environmental loss contingencies. + References Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 410 -SubTopic 30 -Section 50 -Paragraph 10 -Subparagraph (d)(3) -URI https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.Y.Q1) -URI https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 410 -SubTopic 30 -Section 50 -Paragraph 7 -URI https://asc.fasb.org/extlink&oid=6393242&loc=d3e13207-110859 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349 Reference 5: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 410 -SubTopic 30 -Section 50 -Paragraph 10 -Subparagraph (d)(1) -URI https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 410 -SubTopic 30 -Section 55 -Paragraph 16 -URI https://asc.fasb.org/extlink&oid=6571209&loc=d3e13703-110860 + Details
Name: | us-gaap_AccrualForEnvironmentalLossContingencies
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Indicates line item in statement of financial position that includes accrual for environmental loss contingency. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 5.Y.Q4) -URI https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751 + Details
Name: | us-gaap_EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumeration
Namespace Prefix: | us-gaap_
Data Type: | enum2:enumerationSetItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount awarded to other party in judgment or settlement of litigation. + References No definition available. + Details
Name: | us-gaap_LitigationSettlementAmountAwardedToOtherParty
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of loss contingency liability. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349 Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 10 -URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349 + Details
Name: | us-gaap_LossContingencyAccrualAtCarryingValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349 + Details
Name: | us-gaap_LossContingencyAccrualProvision
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of damages awarded to the plaintiff in the legal matter. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 9 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349 + Details
Name: | us-gaap_LossContingencyDamagesAwardedValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of damages paid to the plaintiff in the legal matter. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 9 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349 + Details
Name: | us-gaap_LossContingencyDamagesPaidValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The value (monetary amount) of the award the plaintiff seeks in the legal matter. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 9 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349 + Details
Name: | us-gaap_LossContingencyDamagesSoughtValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | teva_DefendantsAxis=teva_FourOtherDefendantsOtherThanTevaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=teva_NationwideSettlementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LossContingenciesByNatureOfContingencyAxis=teva_EosinophilicEsophagitisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=teva_AndroGelRateAtOnePercentageMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |